Chief executive officers of major multinational pharmaceutical and biotechnology corporations earn some of the highest executive compensation packages in the corporate world, reflecting the immense capital risks, regulatory hurdles, and R&D investments required to bring new medicines to market. Total annual compensation for pharma CEOs routinely spans between 15 million and 30 million US dollars, consisting of baseline cash salaries, lucrative annual cash bonuses, and extensive stock options or restricted equity awards tied directly to clinical trial successes, FDA approvals, and long-term shareholder returns.